Search Results
Oct 07, 2025, 07:00 ET TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress
Registrational Phase 2 Study for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer and in Phase 1 for other CLDN6+ Cancers including Non-Small Cell Lung Cancer Updated Data for TORL-1-23 in Patients with CLDN6+ Advanced
More news about: TORL Biotherapeutics LLC
Oct 07, 2025, 07:00 ET Children's Medical Center Dallas Ranked Among Best Children's Hospitals, Nationally Recognized in All Pediatric Specialties by U.S. News & World Report
Pulmonology & Lung Surgery: No. 26
More news about: Children’s Health
Oct 07, 2025, 03:30 ET Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting
More news about: Resolution Therapeutics
Oct 06, 2025, 09:04 ET NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month
Neck Cancers Hepatocellular Carcinoma Kidney Cancer Non-Small Cell Lung Cancer Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Prostate Cancer
More news about: National Comprehensive Cancer Network
Oct 06, 2025, 09:04 ET NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month
Neck Cancers Hepatocellular Carcinoma Kidney Cancer Non-Small Cell Lung Cancer Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Prostate Cancer
More news about: National Comprehensive Cancer Network
Oct 06, 2025, 09:00 ET AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
during treatment with BOTOX for spasticity or for detrusor overactivity associated with a neurologic condition. The risk of developing lung disease in patients with reduced lung function is increased in patients receiving BOTOX. Cornea problems have been reported.
More news about: AbbVie
Oct 03, 2025, 12:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
"announce[ing] topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease." The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint. On this news,
More news about: Pomerantz LLP
Oct 03, 2025, 12:28 ET IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications.
More news about: IceCure Medical
Oct 03, 2025, 12:19 ET IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications.
More news about: IceCure Medical
Oct 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments
More news about: Pomerantz LLP
Oct 03, 2025, 06:42 ET September in Review: 11 Top Health Press Releases
Galvanize Therapeutics raised $100 million in funding to continue improvements in treating both cancer and chronic lung disease. Breast Cancer Awareness Month: Charitable organizations got a head start on spreading
More news about: PR Newswire
Oct 03, 2025, 02:00 ET The Department of Clinical and Molecular Medicine of Sapienza University of Rome, Takis and Tethis start a collaboration to advance HER3-targeted therapies and diagnostics
S.p.A. today announce a joint initiative, to accelerate research on HER3-targeted therapies and advance the development of companion diagnostics for lung cancer patients.
More news about: Tethis S.p.A.
Oct 02, 2025, 19:30 ET The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot as a Pinnacle Lifetime Member
lives of cancer patients through his precision, compassion, and commitment to care. Treating adult patients facing a wide range of cancers including lung, breast, head and neck, gastrointestinal, prostate, brain, and spine, Dr. Pennock is known for his meticulous attention to detail and his ability to
More news about: The Inner Circle
Oct 02, 2025, 18:37 ET FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
fatigue/asthenia. About Small Cell Lung Cancer In the U.S., approximately 13 percent of lung cancers are small cell.2 Approximately 30,000 new cases of small cell lung cancer (SCLC) are reported in the U.S. each year.2,3 The
More news about: Jazz Pharmaceuticals plc
Oct 02, 2025, 14:58 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Oct 02, 2025, 14:29 ET Shield of Odin Responds to VA Backlog: Offering Veterans an Alternative Pathway to Overcome Delayed Disability Claims
how quickly those numbers can rise, and how devastating the wait can be," said Ryan Hawley, CEO of Shield of Odin. "For a veteran with lung disease from burn pit exposure or PTSD from combat service, being forced to wait 18 months or longer is not simply a delay; it's a barrier to care,
More news about: Odin Industries LLC
Oct 02, 2025, 09:45 ET Merck Manuals Shares What Patients Need to Know About COPD
can be done about it, says Wise. The reality is, there are effective treatments that can improve exercise capacity, reduce symptoms, improve overall lung function, and extend survival. COPD often takes years to progress, and the earlier individuals can take proactive steps to address it, the better, says
More news about: The Merck Manuals
Oct 02, 2025, 07:50 ET AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing
BRCA-mutated and BRCAness tumors, we believe NB-A002 offers a superior alternative to PARP inhibitors with potential treatments across ovarian, breast, lung and other solid tumors. The global DDR therapy market is valued at $8.3 billion today and expected to reach $19.5 billion by
More news about: NYB Holdings Limited
Oct 01, 2025, 17:31 ET CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight
Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report
More news about: DelveInsight Business Research, LLP
Oct 01, 2025, 09:00 ET Flint Cooper Cohn Thompson & Miracle Announces Addition of Accomplished Asbestos Litigator Jonathan Armour
division. Jonathan brings 15 years of experience in toxic tort litigation, particularly in asbestos-related cases involving mesothelioma and primary lung cancer.
More news about: Flint Cooper
Oct 01, 2025, 08:00 ET LungCanSeek: New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer
specificity of 90.3% in detecting lung cancer. Subtype Identification: The test successfully classified lung cancer subtypes—lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and small cell lung cancer (SCLC)—with 77.4% accuracy.
More news about: SeekIn Inc
Oct 01, 2025, 07:00 ET Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care
chronically ill (SSBCI). SSBCI conditions include but are not limited to: hypertension, hyperlipidemia, diabetes, cardiovascular disorders, and chronic lung disorders. Eligibility is determined by whether you have a chronic condition associated with the benefit(s). Standards and conditions vary for each
More news about: CVS Health
Oct 01, 2025, 06:40 ET Scleroderma Market to Reach US$ 4,103.07 Million by 2033 as Biologics, Targeted Therapies, and Early Diagnosis Transform Patient Outcomes | Report by DataM Intelligence
the lungs, kidneys, and cardiovascular system make it the focal point of research investments. Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) remain critical therapeutic targets. Localized Scleroderma, valued at US$ 835 million,
More news about: DataM Intelligence 4 Market Research LLP
Oct 01, 2025, 06:09 ET Data Show Promising Results for RSV Prevention Methods, Keeping Babies Out of the Hospital
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Oct 01, 2025, 06:03 ET Karmanos Thinks Pink, Recognizes Breast Cancer Awareness Month in October
59,080 new cases of ductal carcinoma in situ. Breast cancer is the second leading cause of cancer death in women, following lung cancer. Breast cancer does occur in men. Around 2,800 new cases of male breast cancer are estimated in the U.S. in 2025.
More news about: Karmanos Cancer Institute